Madrigal pharmaceuticals provides corporate updates and reports fourth quarter and full year 2023 financial results

Conshohocken, pa., feb. 28, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results.
MDGL Ratings Summary
MDGL Quant Ranking